溶质载体介导纳米药物载体跨越血脑屏障的研究进展

李震; 刘彦滟; 赵岩; 沈雁

doi:10.11665/j.issn.1000-5048.20220203

溶质载体介导纳米药物载体跨越血脑屏障的研究进展

中国药科大学药学院药剂系，南京 210009

基金项目: 国家自然科学基金资助项目（No.81972892）

计量
- 文章访问数: 306
- HTML全文浏览量: 20
- PDF下载量: 544
出版历程
- 收稿日期: 2021-07-08
- 修回日期: 2022-03-10
- 刊出日期: 2022-04-24

Research progress of solute carriers in mediating nanomedicine across the blood-brain barrier

Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81972892)

摘要

摘要: 血脑屏障作为大脑和体循环间的结构性屏障，阻止大分子和大多数小分子药物进入大脑，给中枢性疾病的治疗带来了困难。血脑屏障上高度表达有各类溶质载体如葡萄糖转运体、氨基酸转运体等，可以将各类营养物质转运进脑内。在纳米药物载体上修饰转运体对应的配体，携带药物通过转运体介导转运的方式跨越血脑屏障，可实现脑部药物的高效率递送，提高中枢类疾病的诊断灵敏度和治疗效果。本文综述了不同类型溶质载体介导脂质体、金属纳米颗粒、聚合物胶束和树状大分子等纳米制剂跨越血脑屏障用于脑部疾病的治疗，并探讨了该策略在未来应用方面所面临的机遇与挑战。
- 纳米药物递送 /
- 血脑屏障 /
- 溶质载体 /
- 转运体介导转运 /
- 进展
Abstract: As a structural barrier between the brain and the systemic circulation, the blood-brain barrier prevents macromolecules and most small-molecule drugs from entering the brain, which make it difficuct to treat central diseases.Various solute carriers such as glucose transporters and amino acid transporters which can transport various nutrients into the brain, are highly expressed on the blood-brain barrier.The ligand corresponding to the transporter is modified on the nano-drug carrier, and the drug is carried across the blood-brain barrier through transporter-mediated transport, which can achieve high-efficiency delivery of drugs to the brain and improve the diagnostic sensitivity and therapeutic effect of central diseases.In this paper, we review different types of solute carriers to mediate nanoformulations such as liposomes, metal nanoparticles, polymer micelles and dendrimers across the blood-brain barrier for the treatment of brain diseases and discuss the opportunities and challenges of this strategy in future applications.
- drug delivery /
- blood-brain barrier /
- solute carrier /
- carrier-mediated transportation /
- advances

HTML全文

参考文献(58)

[1]	. Artif Cells Nanomed Biotechnol，2019，47（1）：1674-1692.
[2]	Abbott NJ，Patabendige AAK，Dolman DEM，et al. Structure and function of the blood-brain barrier［J］. Neurobiol Dis，2010，37（1）：13-25.
[3]	Azarmi M，Maleki H，Nikkam N，et al. Transcellular brain drug delivery：a review on recent advancements［J］. Int J Pharm，2020，586：119582.
[4]	Hersh DS，Wadajkar AS，Roberts N，et al. Evolving drug delivery strategies to overcome the blood brain barrier［J］. Curr Pharm Des，2016，22（9）：1177-1193.
[5]	Kou LF，Hou YX，Yao Q，et al. L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN₂［J］. Artif Cells Nanomed Biotechnol，2018，46（8）：1605-1616.
[6]	Niu Q，Sun QS，Qiu ZX，et al. Progress of SLC13A5 as a potential pharmacological target of metabolic diseases［J］. J China Pharm Univ（中国药科大学学报），2020，51（5）：607-613.
[7]	Hediger MA，Clémen?on B，Burrier RE，et al. The ABCs of membrane transporters in health and disease （SLC series）：introduction［J］. Mol Aspects Med，2013，34（2/3）：95-107.
[8]	Zhang Y，Zhou HY，Chen JL. Cross-layer access control in publish/subscribe middleware over software-defined networks［J］. Comput Commun，2019，134：1-13.
[9]	Hu CL，Tao L，Cao XZ，et al. The solute carrier transporters and the brain：physiological and pharmacological implications［J］. Asian J Pharm Sci，2020，15（2）：131-144.
[10]	Duan HC，Wang J. Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3［J］. J Pharmacol Exp Ther，2010，335（3）：743-753.
[11]	Takahashi K，Foster JB，Lin CLG. Glutamate transporter EAAT2：regulation，function，and potential as a therapeutic target for neurological and psychiatric disease［J］. Cell Mol Life Sci，2015，72（18）：3489-3506.
[12]	Schulz A，Beyhl D，Marten I，et al. Proton-driven sucrose symport and antiport are provided by the vacuolar transporters SUC4 and TMT1/2［J］. Plant J，2011，68（1）：129-136.
[13]	Hervé F，Ghinea N，Scherrmann JM. CNS delivery via adsorptive transcytosis［J］. AAPS J，2008，10（3）：455-472.
[14]	Masserini M. Nanoparticles for brain drug delivery［J］. ISRN Biochem，2013，2013：238428.
[15]	Chen Y，Liu LH. Modern methods for delivery of drugs across the blood-brain barrier［J］. Adv Drug Deliv Rev，2012，64（7）：640-665.
[16]	Yu YJ，Zhang Y，Kenrick M，et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target［J］. Sci Transl Med，2011，3（84）：84ra44.
[17]	Xie JB，Gonzalez-Carter D，Tockary TA，et al. Dual-sensitive nanomicelles enhancing systemic delivery of therapeutically active antibodies specifically into the brain［J］. ACS Nano，2020，14（6）：6729-6742.
[18]	Nair LV，Nair RV，Shenoy SJ，et al. Blood brain barrier permeable gold nanocluster for targeted brain imaging and therapy：an in vitro and in vivo study［J］. J Mater Chem B，2017，5（42）：8314-8321.
[19]	Xiao WJ，Fu QY，Zhao Y，et al. Ascorbic acid-modified brain-specific liposomes drug delivery system with “lock-in” function［J］. Chem Phys Lipids，2019，224：104727.
[20]	Liu QJ，Zhou L，Lu RX，et al. Biotin and glucose co-modified multi-targeting liposomes for efficient delivery of chemotherapeutics for the treatment of glioma［J］. Bioorg Med Chem，2021，29：115852.
[21]	Li JF，Guo YB，Kuang YY，et al. Choline transporter-targeting and co-delivery system for glioma therapy［J］. Biomaterials，2013，34（36）：9142-9148.
[22]	Maussang D，Rip J，van Kregten J，et al. Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo［J］. Drug Discov Today Technol，2016，20：59-69.
[23]	Wang SB，An J，Dong WW，et al. Glucose-coated berberine nanodrug for glioma therapy through mitochondrial pathway［J］. Int J Nanomedicine，2020，15：7951-7965.
[24]	Cordain L，Watkins BA，Mann NJ. Fatty acid composition and energy density of foods available to African hominids. Evolutionary implications for human brain development［J］. World Rev Nutr Diet，2001，90：144-161.
[25]	Benarroch EE. Brain glucose transporters：implications for neurologic disease［J］. Neurology，2014，82（15）：1374-1379.
[26]	Béduneau A，Saulnier P，Benoit JP. Active targeting of brain tumors using nanocarriers［J］. Biomaterials，2007，28（33）：4947-4967.
[27]	Patching SG. Glucose transporters at the blood-brain barrier：function，regulation and gateways for drug delivery［J］. Mol Neurobiol，2017，54（2）：1046-1077.
[28]	Hao ZF，Cui YX，Li MH，et al. Liposomes modified with P-aminophenyl-α-D-mannopyranoside：a carrier for targeting cerebral functional regions in mice［J］. Eur J Pharm Biopharm，2013，84（3）：505-516.
[29]	Qu BY，Li XC，Guan M，et al. Design，synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes［J］. Eur J Med Chem，2014，72：110-118.
[30]	Fu QY，Zhao Y，Yang ZZ，et al. Liposomes actively recognizing the glucose transporter GLUT 1 and integrin α v β 3 for dual-targeting of glioma［J］. Arch Pharm （Weinheim），2019，352（2）：e1800219.
[31]	Arora S，Layek B，Singh J. Design and validation of liposomal ApoE2 gene delivery system to evade blood-brain barrier for effective treatment of Alzheimer''s disease［J］. Mol Pharm，2021，18（2）：714-725.
[32]	Sintov AC，Velasco-Aguirre C，Gallardo-Toledo E，et al. Metal nanoparticles as targeted carriers circumventing the blood-brain barrier［J］. Int Rev Neurobiol，2016，130：199-227.
[33]	Wang LH，Zhao Y，Lu RX，et al. Preparation and characterization of novel brain targeting magnetic nanoparticles modified with ascorbic acid［J］. Nano，2018，13（1）：1850008.
[34]	Ugur Yilmaz C，Emik S，Orhan N，et al. Targeted delivery of lacosamide-conjugated gold nanoparticles into the brain in temporal lobe epilepsy in rats［J］. Life Sci，2020，257：118081.
[35]	Khan AR，Yang XY，Fu MF，et al. Recent progress of drug nanoformulations targeting to brain［J］. J Control Release，2018，291：37-64.
[36]	Anraku Y，Kuwahara H，Fukusato Y，et al. Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain［J］. Nat Commun，2017，8（1）：1001.
[37]	Niu JX，Wang AD，Ke ZC，et al. Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating［J］. J Drug Target，2014，22（8）：712-723.
[38]	Nance E，Zhang F，Mishra MK，et al. Nanoscale effects in dendrimer-mediated targeting of neuroinflammation［J］. Biomaterials，2016，101：96-107.
[39]	Ruan SB，Qin L，Xiao W，et al. Acid-responsive transferrin dissociation and GLUT mediated exocytosis for increased blood-brain barrier transcytosis and programmed glioma targeting delivery［J］. Adv Funct Mater，2018，28（30）：1802227.
[40]	Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems［J］. NeuroRx，2005，2（1）：54-62.
[41]	Boado RJ，Li JY，Nagaya M，et al. Selective expression of the large neutral amino acid transporter at the blood-brain barrier［J］. Proc Natl Acad Sci U S A，1999，96（21）：12079-12084
[42]	Kanai Y，Segawa H，Miyamoto KI，et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen （CD98）［J］. J Biol Chem，1998，273（37）：23629-23632.
[43]	Kobayashi K，Ohnishi A，Promsuk J，et al. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells［J］. Neurosurgery，2008，62（2）： 493-503；discussion503-4.
[44]	Dickens D，Chiduza GN，Wright GSA，et al. Modulation of LAT1 （SLC7A5） transporter activity and stability by membrane cholesterol［J］. Sci Rep，2017，7：43580.
[45]	Bhunia S，Vangala V，Bhattacharya D，et al. Large amino acid transporter 1 selective liposomes of l-DOPA functionalized amphiphile for combating glioblastoma［J］. Mol Pharm，2017，14（11）：3834-3847.
[46]	Li L，Di XS，Zhang SW，et al. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting［J］. Colloids Surf B Biointerfaces，2016，141：260-267.
[47]	Zhang YG，Li S，Liu HL，et al. Enzyme-like properties of gold clusters for biomedical application［J］. Front Chem，2020，8：219.
[48]	Nair LV，Nair RV，Shenoy SJ，et al. Blood brain barrier permeable gold nanocluster for targeted brain imaging and therapy：an in vitro and in vivo study［J］. J Mater Chem B，2017，5（42）：8314-8321.
[49]	Vyas A，Jain A，Hurkat P，et al. Targeting of AIDS related encephalopathy using phenylalanine anchored lipidic nanocarrier［J］. Colloids Surf B Biointerfaces，2015，131：155-161.
[50]	Zeisel SH. Nutritional importance of choline for brain development［J］. J Am Coll Nutr，2004，23（6 Suppl）：621S-626S.
[51]	Li JF，Yang HY，Zhang YJ，et al. Choline derivate-modified doxorubicin loaded micelle for glioma therapy［J］. ACS Appl Mater Interfaces，2015，7（38）：21589-21601.
[52]	Venishetty VK，Samala R，Komuravelli R，et al. Β-Hydroxybutyric acid grafted solid lipid nanoparticles：a novel strategy to improve drug delivery to brain［J］. Nanomedicine，2013，9（3）：388-397.
[53]	Aoyama K. Glutathione in the brain［J］. Int J Mol Sci，2021，22（9）：5010.
[54]	Rip J，Chen LD，Hartman R，et al. Glutathione PEGylated liposomes：pharmacokinetics and delivery of cargo across the blood-brain barrier in rats［J］. J Drug Target，2014，22（5）：460-467.
[55]	Han GH，Zhang BL，Zhang H，et al. The synthesis and characterization of glutathione-modified superparamagnetic iron oxide nanoparticles and their distribution in rat brains after injection in substantia nigra［J］. J Mater Sci Mater Med，2018，30（1）：5.
[56]	Vadlapudi AD，Vadlapatla RK，Mitra AK. Sodium dependent multivitamin transporter （SMVT）：a potential target for drug delivery［J］. Curr Drug Targets，2012，13（7）：994-1003.
[57]	Tong XY，Huang CY，Yao J，et al. Distribution of nimodipine microemulsion in mice in vivo and evaluation on its targeting performance［J］. J China Pharm Univ（中国药科大学学报），2002，33（4）：31-34.
[58]	Pottiez G，Flahaut C，Cecchelli R，et al. Understanding the blood-brain barrier using gene and protein expression profiling technologies［J］. Brain Res Rev，2009，62（1）：83-98.